Mr. Paterson joined Anteris in October 2014 as a Non-Executive Director, served as the Chair from February 2016 to March 2017, and served as our interim Chief Executive Officer commencing in May 2016 before being appointed Chief Executive and Director in 2017. Mr. Paterson was appointed Vice Chairman and CEO in March 2025.
Mr. Paterson commenced as Chair of v2vmedtech, inc. from April 2023. Prior to joining Anteris, Mr. Paterson held senior positions at Merck KGaA (“Merck”), a multinational science and technology company, from 2005 to 2013, including as President of Europe, Canada and Australia, President of Emerging Markets, President of Japan and President of Cardiovascular Medicine.
From 1999 until 2005, Mr. Paterson served at Roche Pharmaceuticals, a multinational healthcare company, in several senior positions, including as Head of Pharmaceuticals in Roche’s South Korean operation and Head of Commercial Operations for Roche China.
Mr. Paterson holds an MBA from the University of Southern Queensland and a degree in Business Studies from the Queensland University of Technology.